media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Keeler’s first Chinese manufacturing base landed and put into operation

Recently, Keeler, a well-known ophthalmic medical equipment brand under the British company Haomai Group, announced that its first manufacturing base in China has been officially completed and put into operation in Shanghai. This measure marks Keeler’s comprehensive launch of localization strategy, which will further enhance its competitiveness in the Chinese market and inject new vitality into the Chinese ophthalmic medical industry. It is reported that Keeler, as an important member of the medical division of Haomai Group, has been committed to providing high-quality examination and treatment equipment for ophthalmologists worldwide. The establishment of the Chinese manufacturing base is a crucial step for Keeler to expand into the Asian market. 01. The first Chinese manufacturing base has been officially completed According to data, Keeler, a British company founded in 1917, is a globally renowned provider of modern medical examination solutions, with its main business covering over 100 countries. In 1953, Keeler ...
- Source: drugdu
- 66
- April 1, 2025
Olin Biotechnology’s net profit attributable to the parent company in 2024 increased by 18.2% to 20.76 million yuan

On March 30, Olin Biotechnology (688319) announced its 2024 annual report. The company’s operating income was 589 million yuan, up 18.7% year-on-year; net profit attributable to the parent company was 20.76 million yuan, up 18.2% year-on-year; net profit attributable to the parent company after deducting non-recurring items was 11.18 million yuan, up 230% year-on-year; net operating cash flow was -9.73 million yuan, down 122.1% year-on-year; EPS (fully diluted) was 0.0511 yuan. In the fourth quarter, the company’s operating income was 202 million yuan, up 40.6% year-on-year; net profit attributable to the parent company successfully turned losses from a loss of 12.73 million yuan in the same period last year, and realized a net profit attributable to the parent company of 16.73 million yuan; net profit attributable to the parent company after deducting non-recurring items successfully turned losses from a loss of 15.54 million yuan in the same period last year, ...
- Source: drugdu
- 53
- April 1, 2025
Trump’s “withdrawal” seriously affects the operation of the organization, and the WHO will lay off some managers

According to a memorandum recently signed by WHO Director-General Tedros, due to the funding cuts by the Trump administration of the United States, the organization’s overall budget has been cut by more than 1/5, and layoffs will have to be taken. Public health and climate change are among the key issues with the broadest consensus in the world today. Trump ordered his withdrawal from the organization during his first term, citing WHO’s improper handling of the COVID-19 pandemic and other international health crises. But later, after Biden took office, he led the United States back to various organizations and international agreements, including the WHO and the Paris Climate Agreement. After Trump took office for the second time on January 20 this year, he immediately signed an executive order requiring measures to be taken as soon as possible to suspend any funding, support and resources to the WHO. This has caused ...
- Source: drugdu
- 54
- April 1, 2025
core product registration in Indonesia and Egyptian technology transfer project both approved

On March 29, Chengda Bio (688739.SH)’s official website reported that in March 2025, the company’s freeze-dried human rabies vaccine (Vero cells) downstream production process technology transfer project (hereinafter referred to as: Egyptian technology transfer project) was officially approved by the Egyptian Food and Drug Administration (EDA). Chengda Bio’s rabies vaccine can be exported to Egypt in two categories: finished products and semi-finished products; at the same time, the company’s freeze-dried human rabies vaccine (Vero cells) also officially obtained the registration approval and on-site inspection approval for the finished product issued by the Indonesian Food and Drug Administration (BPOM). Access to Indonesia marks that the company has achieved new breakthroughs in the Southeast Asian market after Thailand, the Philippines, Vietnam and other countries, and has penetrated into the core market of ASEAN. Egypt’s technology transfer project approved, overseas localized production enters a new stage Despite the rapid development of the global ...
- Source: drugdu
- 58
- April 1, 2025
Hisun Pharmaceuticals will turn losses into profits in 2024, with a net profit of 601 million yuan

On the evening of March 28, Hisun Pharmaceuticals (600267) announced its 2024 annual report. The report shows that the company achieved operating income of 9.787 billion yuan and a net profit of 601 million yuan in 2024. The company said that the performance was able to turn losses into profits, mainly due to the promotion of preparation products, the growth of pharmaceutical raw material business, the increase in sales profit, and the company’s improvement of management efficiency, optimization of resource allocation and utilization efficiency. At the same time, Hisun Pharmaceuticals actively returns to shareholders, and plans to pay cash dividends of 2.10 yuan (including tax) for every 10 shares in 2024. In addition, in 2024, the company adopted a centralized bidding method to implement a share repurchase amount of 96.4589 million yuan, and the cash dividend and repurchase amount totaled 342 million yuan, accounting for 56.87% of the net profit ...
- Source: drugdu
- 57
- April 1, 2025
China Chongqing International Pharmaceutical Machinery Expo Spring (CIPM)

Organiser: China Pharmaceutical Equipment Industry Association Time: April 23-25, 2025 Address: No. 66 Yuelai Avenue, Yubei District, Chongqing Exhibition hall: Chongqing International Expo Center Product range: API Equipment & Machinery: Reaction equipment, tower equipment, crystallization equipment, separation machinery, extraction equipment, heat exchangers, evaporation equipment, distillation equipment, drying machinery, storage equipment, sterilization equipment. Formulation Machinery: Granule machinery, tablet press machines, capsule filling machines, powder injectable machinery, small/large-volume injectable equipment, pill machinery, suppository machinery, ointment machinery, oral liquid machinery, aerosol machinery, ophthalmic preparation machinery, film-coating machinery. Pharmaceutical Packaging Machinery & Materials: Direct packaging machinery, outer packaging machinery, pharmaceutical packaging material manufacturing equipment, packaging materials, packaging production lines, packaging software, integrated packaging solutions. Pharmaceutical Water/Gas Equipment: Process gas/steam equipment, purified water systems, water-for-injection systems, ion exchange equipment. Pharmaceutical Crushing Equipment: Mechanical crushers, jet mills, grinding mills, cryogenic crushers. Traditional Chinese Medicine Processing Machinery: Cleaning machinery, cutting machinery, roasting/frying machinery, drying equipment. Drug Testing Equipment: Hardness testers, ...
- Source: drugdu
- 75
- April 1, 2025
Why does China Biotech refuse to repay the $224 million advance payment?

On March 24th, Clover Biotech announced that its wholly-owned subsidiary Clover Hong Kong had received a written notice from the Global Alliance for Vaccines and Immunization (Gavi) dated March 21, 2025, one month in advance. The notice claims that Gavi unilaterally terminated the pre order agreement and a claim letter dated March 21, 2025, which demanded that Clover Hong Kong refund the advance payment of $224 million (the “Advance Payment Amount”). San Ye Cao Biological announced that the company has refused the request for a refund, believing that such a request lacks basis based on the terms of the pre order agreement, and will do its utmost to safeguard its own rights and interests. To the best of Clover Biology’s knowledge, as of the date of this announcement, no legal proceedings have been initiated regarding the aforementioned claims. 01. Irreversible advance payment Before clarifying why Clover Biology confidently refused to ...
- Source: drugdu
- 55
- March 31, 2025
4.9 billion, Siemens Healthineers makes big moves

Recently, Siemens Healthineers and the Canadian government announced a major collaboration, signing a cooperation agreement with a total investment of over 4.9 billion RMB. This new ‘value partnership’ is jointly established with the Alberta Cancer Foundation, aiming to improve healthcare service efficiency through technological innovation. Collaboration worth 4.9 billion yuan The western region of Canada is facing dual challenges of population growth and aging, with the number of cancer cases constantly increasing. To address this situation, the Alberta government will invest 800 million Canadian dollars (approximately 4.03 billion RMB) over the next eight years to fully support early detection of cancer, reduce patient waiting times, and strive to establish Alberta’s leadership position in cancer research and innovation. Siemens Healthineers will comprehensively replace outdated imaging and tumor treatment equipment throughout Alberta, while introducing innovative technologies and consulting services as solutions. This measure will significantly improve the level of medical facilities in ...
- Source: drugdu
- 57
- March 31, 2025
Maiwei Biopharma and Junshi Biopharma signed supplementary terms of the cooperation agreement on adalimumab injection

On March 27, Maiwei Biopharma (688062) issued an announcement that on March 26, 2025, the company and its wholly-owned subsidiaries signed a supplementary agreement on the cooperative development agreement on adalimumab injection with Junshi Biopharma and its wholly-owned subsidiaries. Specifically, the company is responsible for the promotion of Junmaikang® and enjoys domestic sales rights at 60% of the net sales and shipment revenue, while Junshi Biopharma is responsible for production and enjoys 40% of the rights. In addition, the two parties share domestic R&D expenses and international sales rights at a ratio of 50%:50%. In the first three quarters of 2024, Maiwei Biopharma achieved revenue of 141 million yuan and a net profit attributable to the parent of -694 million yuan. https://finance.eastmoney.com/a/202503273358105290.html
- Source: drugdu
- 55
- March 31, 2025
Alphamab Oncology’s counterattack

On March 25, Corning Jeol released its 2024 annual performance announcement, delivering an impressive report card: full-year revenue soared to 640 million yuan, a year-on-year increase of 192%, and achieved a net profit of 166 million yuan, successfully turning losses into profits. Successfully turned losses into profits According to Corning Ong’s financial report, total revenue in 2024 reached 640 million yuan, nearly double the 219 million yuan in 2023. Among them, licensing fee income performed particularly well, soaring from 7 million yuan in 2023 to 464 million yuan, becoming the main driving force for revenue growth. However, sales and royalty revenue of KN035 (Envolimab) decreased to 159 million yuan, reaching 196 million yuan in 2023. In terms of profit, the company successfully turned losses into profits, recording a net profit of 166 million yuan for the year, which was a milestone breakthrough compared to a loss of 210 million yuan ...
- Source: drugdu
- 53
- March 31, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.